A paper by psychologists at the University of Pennsylvania's Annenberg Public Policy Center suggests that public perception of governmental support for comprehensive drug policies, including harm reduction, is a postive predictor of trust in local government. 

Bar Harbor, Maine — A new study led by MDI Biological Laboratory identifies ML233 as a potent inhibitor of melanin production, offering promise for development of new treatments for pigment-related skin disorders and one melanoma subtype. The compound showed strong effects at low doses in zebrafish, mouse and and human cell models, highlighting potential for dermatological therapies.

Researchers have completed a comprehensive natural history study of SCN8A-related disorders, which represent a spectrum of neurological symptoms. The study, using retrospective clinical information analyzed through novel data analysis methods, revealed a range of seizure types and neurodevelopmental features, and identifies potential targets for future clinical trials.